NCT00516893 - Natalizumab High Titer Immunogenicity and Safety | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

December 31, 2007

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL

BG00002-E (natalizumab high titer)

Trial Locations (13)

Research Site, New York

Research Site, Buffalo

Research Site, Pittsburgh

Research Site, Philadelphia

Research Site, Washington D.C.

Research Site, Charlotte

Research Site, Atlanta

Research Site, Maitland

Research Site, Miami

Research Site, Farmington Hills

Research Site, Milwaukee

Research Site, Dallas

Research site, Round Rock